Drug intelligence / Profile preview

Ixprim

Development stage
Phase 4
Lead developer
Grünenthal
Modality
Small Molecules
Administration
Oral
01

Overview

Ixprim is a fixed-dose combination analgesic consisting of tramadol hydrochloride and paracetamol (acetaminophen). Tramadol is a centrally acting synthetic opioid analgesic that functions as a mu-opioid receptor agonist and a weak inhibitor of the neuronal reuptake of norepinephrine and serotonin. Paracetamol is a non-opioid analgesic and antipyretic whose mechanism likely involves the inhibition of prostaglandin synthesis in the central nervous system. This combination is indicated for the management of moderate to severe pain, providing a synergistic effect that allows for lower doses of each component compared to monotherapy. In a Phase 4 clinical trial (NCT01782846) conducted by Hopital Foch, Ixprim was evaluated for its analgesic efficacy in emergency department patients presenting with moderate pain, specifically comparing its performance against a codeine/paracetamol combination (Dafalgan-Codeine).

Brand names
Ixprim
Other names
tramadol + paracetamoltramadol + acetaminophentramadol hydrochloride + paracetamol
02

Targets

NET (Norepinephrine Transporter)SERT (Sodium-dependent serotonin transporter)MOR (Mu opioid receptor)PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on Ixprim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ixprim.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call